Nabriva Therapeutics Announces Completion of Enrollment in LEAP 2, a Phase 3 Clinical Trial Evaluating Oral Lefamulin for the Treatment of Community-Acquired Bacterial Pneumonia in Adults

Company remains on track to report topline results in Spring 2018 DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Dec. 04, 2017 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to


Leave a Reply

Your email address will not be published.